IPH 1101 Uses, Dosage, Side Effects and more
IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset. IPH 1101 is the most advanced drug candidate of the γδ T cell platform
IPH 1101 potentiates the direct cytotoxic activity of Vγ9Vδ2 T cells against a large number of tumor cell lines and also triggers the synthesis of pro-inflammatory cytokines - thus inducing the recruitment of other cell effectors and facilitating implementation of an adaptive response.
| Attribute | Details |
|---|---|
| Trade Name | IPH 1101 |
| Generic | IPH 1101 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in hepatitis (viral, C), leukemia (myeloid), and lymphoma (non-hodgkin's).
